News


Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicat

Wednesday , 31 July 2019

Proceeds will be used to grow company’s team in Lyon and Boston, to advance its current programs in hypoparathyroidism and severe insulin resistance into clinical development, and to further strengthen its product portfolio in rare endocrine and metabolic diseases   Lyon, France, July 31, 2019 - Alizé Pharma 3, a company specialized in developing therapeutic peptides for rare endocrine and metabolic diseases, today announces that it has completed a €67 million ...

READ MORE...


Pherecydes Pharma and BIOASTER join forces to explore the use of phage therapy to treat complicated

Tuesday , 16 July 2019

Romainville and Lyon, France, July 16, 2019 - Pherecydes Pharma and BIOASTER, the French Technology Research Institute (TRI) for Microbiology and Infectious Diseases, announce the signing of a collaboration agreement. This project, called PhagUTI, is a unique opportunity for the partners to capitalize on BIOASTER’s unique expertise in pre-clinical models and the extensive experience of Pherecydes in the selection, characterization and production of bacteriophages. In t...

READ MORE...


Domain Therapeutics appoints Xavier Leroy as chief technology officer 

Wednesday , 10 July 2019

Drug discovery expert will be responsible for developing Domain’s platforms and driving technology-based projects to support Domain’s development and growth   Strasbourg, France, July 8, 2019 – Domain Therapeutics, a biopharmaceutical company specialized in the discovery and development of new drug candidates targeting transmembrane receptors in neurology, oncology and rare diseases, today announces the appointment of Xavier Leroy as chief technology ...

READ MORE...


Domain Therapeutics appoints Xavier Leroy as chief technology officer 

Monday , 08 July 2019

Drug discovery expert will be responsible for developing Domain’s platforms and driving technology-based projects to support Domain’s development and growth   Strasbourg, France, July 8, 2019 – Domain Therapeutics, a biopharmaceutical company specialized in the discovery and development of new drug candidates targeting transmembrane receptors in neurology, oncology and rare diseases, today announces the appointment of Xavier Leroy as chief technology ...

READ MORE...


Oncovita signs exclusive licensing agreement with Institut Pasteur 

Tuesday , 02 July 2019

Agreement will cover development and marketing of oncolytic virotherapies   Paris, France, July 2, 2019 – Oncovita, a biotech company dedicated to the development of life-saving new treatments, in particular anti-cancer therapies, announces today that it has entered into a licensing agreement with Institut Pasteur, granting it an exclusive worldwide license to develop, manufacture and commercialize therapies based on the immuno-oncolytic measles virus platform. Financial terms ...

READ MORE...


Domain Therapeutics strengthens its scientific advisory board with leading GPCR and disease expert

Monday , 24 June 2019

Strasbourg, France, June 24, 2019 – Domain Therapeutics today announces the appointment of world-renowned GPCR (G protein-coupled receptors) and drug discovery and development experts to its Scientific Advisory Board (SAB): Pr. Silvio Gutkind, Pr. Morley Hollenberg and Pr. Brigitte Kieffer.   Dr. Youssef Bennani, chairman of Domain’s board of directors, will also join the SAB, which will benefit from his expertise in drug discovery and development a...

READ MORE...


Domain Therapeutics appoints Sylvie Ryckebusch to board of directors

Wednesday , 12 June 2019

Seasoned business executive will bring important insights in licensing strategy and contribute to Domain’s next phase of development   Strasbourg, France, June 12, 2019 – Domain Therapeutics, a biopharmaceutical company specialized in the discovery and development of new drug candidates targeting transmembrane receptors for unmet needs in neurology, oncology and rare diseases, today announces the appointment of Sylvie Ryckebusch to its board of directors.   Sylvie ...

READ MORE...


Vygon Asia donates chemo ports to Mount Miriam Cancer Hospital in Malaysia

Tuesday , 11 June 2019

Vygon Asia donates chemo ports to Mount Miriam Cancer Hospital in Malaysia Value Life – One Port One Life Program   Penang, Malaysia, June 11, 2019 – Vygon Asia today announces that it has donated 50 Vygon Polysite ISP implantable ports for patients undergoing chemotherapy at the Mount Miriam Cancer Hospital under the One Port One Life program.     Vygon’s Polysite ISP port is usually offered when a patient’s medical treatment requires regular...

READ MORE...


Servier appoints Yposkesi for lentiviral vector GMP-manufacturing in CAR-T cell development technolo

Wednesday , 05 June 2019

Service agreement gives Servier access to Yposkesi’s robust production capacity Suresnes and Corbeil-Essonnes, France, June 5, 2019 – Servier, an international independent pharmaceutical company, and Yposkesi, a leading CDMO for gene therapy viral vector manufacturing, today announce that they have signed a manufacturing service agreement. Servier selected Yposkesi to develop and GMP manufacture lentiviral vectors to support allogenic CAR-T cell technology development. Cel...

READ MORE...


Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ata

Tuesday , 04 June 2019

Mataró, Barcelona, Spain and Charleroi, Belgium, June 4, 2019 - Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that the first patient has been dosed with its lead candidate, leriglitazone (MIN-102), in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia.  This first patient was dosed at the end of April at the Hospital La Paz (Madrid) by a team headed up by Dr. Francisco Javier Rodríguez de R...

READ MORE...


Featured Employers

© 2019 Jobsinpharma - 4ward Technologies Ltd All rights reserved.